81/297US=22 / Urologia
Cho D, Mier JW, Atkins MB. PI3K/AKt/mTOR pathway: a growth and proliferation pathway. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 267-85. ISBN 978-1-58829-737-2.

INIBIDORES PI3K; RCC; HIPERATIVACAO DO AKT/PI3K; ATIVIDADE AKT; TEMSIROLIMUS

82/297US=27 / Clin/Médica
FitzGerald GA. Prostaglandinas, aspirina e compostos correlatos. In: Goldman L, Ausiello D, editors. Cecil medicina. 23ª ed. Rio de Janeiro: Elsevier, 2009. p. 231-41. ISBN 85-3523677-4.

PROSTAGLANDINA; CICLOOXIGENASE; TROMBOXANO A2; PROSTACICLINA; PROSTAGLANDINA I2; PROSTAGLANDINA D2; PROSTAGLANDINA E2; PROSTAGLANDINA F2-ALFA; ISOEICOSANOIDES; INIBIDORES DE CICLOOXIGENASE; ASPIRINA; ANTI-INFLAMATORIOS NAO ESTEROIDAIS; INIBIDORES DE COX-2

83/297US=27 / Clin/Médica
Karp DR, Holers VM. O papel do complemento na saúde e na doença. In: Goldman L, Ausiello D, editors. Cecil medicina. 23ª ed. Rio de Janeiro: Elsevier, 2009. p. 338-45. ISBN 85-3523677-4.

SISTEMA COMPLEMENTO; ATIVACAO DO COMPLEMENTO; COMPLEXO DE ATAQUE A MEMBRANA; INIBIDORES DO COMPLEMENTO

84/297US=8 / Laboratório
Lecker SH, Saric T, Goldberg AL. Protein degradation in cells. In: Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, Silberstein LE, McGlave P, Heslop HE. Hematology: basic principles and practice. 5th ed. Philadelphia: Churchill Livingstone, 2009. p. 34-41. ISBN 978-0-443-06715-0.

DEGRADACAO DE PROTEINAS; PROTEOLISE LISOSSOMAL; CONJUGACAO DA UBIQUITINA; INIBIDORES DE PROTEASSOMA; TERAPIA DO CANCER; DEGRADACAO ASSOCIADA AO RETICULO ENDOPLASMATICO; PROTEOLISE EM MITOCONDRIA; QUEBRA DE PROTEINA MUSCULAR; CAQUEXIA

85/297US=8 / Laboratório
Lee WMF, Dang CV. Control of cell division. In: Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, Silberstein LE, McGlave P, Heslop HE. Hematology: basic principles and practice. 5th ed. Philadelphia: Churchill Livingstone, 2009. p. 61-71. ISBN 978-0-443-06715-0.

CONTROLE DA DIVISAO CELULAR; TRANSDUCAO DE SINAL; PROLIFERACAO DE CELULAS; CICLO DA DIVISAO CELULAR; RB; FASE S; FASE M; FASE G1; FASE G2; CICLINAS; QUINASES DEPENDENTES DA CICLINA; REGULACAO DO CICLO CELULAR; INIBIDORES DE QUINASES DEPENDENTES DA CICLINA

86/297US=8 / Laboratório
Gerson SL, Bhalla KN, Grant S, Natarajan K, Creger RJ, DeRemer D. Pharmacology and molecular mechanisms of antineoplastic agents for hematologic malignancies. In: Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, Silberstein LE, McGlave P, Heslop HE. Hematology: basic principles and practice. 5th ed. Philadelphia: Churchill Livingstone, 2009. p. 839-98. ISBN 978-0-443-06715-0.

FARMACOLOGIA; MECANISMOS MOLECULARES; AGENTES ANTINEOPLASICOS; DOENCAS HEMATOLOGICAS; CINETICA CELULAR; CICLO CELULAR; CRESCIMENTO DO TUMOR; AGENTES QUIMIOTERAPEUTICOS; APOPTOSE; RESISTENCIA A DROGAS; AGENTES ALQUILANTES; AGENTES ANTIMICROTUBULOS; ANTIMETABOLITOS; INIBIDORES DA TOPOISOMERASE; ANALOGOS DE PLATINA

87/297US=8 / Laboratório
Drohan WN, Clark DB. Preparation of plasma-derived and recombinant human plasma proteins. In: Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, Silberstein LE, McGlave P, Heslop HE. Hematology: basic principles and practice. 5th ed. Philadelphia: Churchill Livingstone, 2009. p. 2239-45. ISBN 978-0-443-06715-0.

PREPARACAO DE DERIVADOS DE PLASMA; PLASMA HUMANO; PLASMA FRESCO CONGELADO; FRACIONAMENTO DE PLASMA; IMUNOGLOBULINAS; GLOBULINAS HIPERIMUNES; CONCENTRADO DE FATOR VIII; CONCENTRADO DO FATOR DE COAGULACAO; CONCENTRADO DE FATOR IX; SELANTES DE FIBRINA; INIBIDORES DE PROTEASE

88/297US=8 / Laboratório
Manno CS, Larson PJ. Transfusion therapy for coagulation factor deficiencies. In: Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, Silberstein LE, McGlave P, Heslop HE. Hematology: basic principles and practice. 5th ed. Philadelphia: Churchill Livingstone, 2009. p. 2247-56. ISBN 978-0-443-06715-0.

TRANSFUSAO; DEFICIENCIAS DE FATORES DA COAGULACAO; HEMOFILIA A; HEMOFILIA B; HEMOFILIA. TRATAMENTO; INIBIDORES DO FATOR VIII; INIBIDORES DO FATOR IX; DOENCA DE VON WILLEBRAND

89/297US=50 / Câncer
Heckman CA, Holopainen T, Alitalo K. Molecular targeting of lymphangiogenesis and tumor metastasis. In: Leong SPL, editor. From local invasion to metastatic cancer: involvement of distant sites through the lymphovascular system. New York: Humana Press, 2009. p. 283-95. ISBN 978-1-60327-086-1.

LINFANGIOGENESE; METASTASE LINFATICA; MOLECULAS LINFANGIOGENICAS; INIBIDORES DA QUINASE DE TIROSINA; RECEPTORES SOLUVEIS; ANTICORPOS BLOQUEADORES

90/297US=50 / Câncer
Berz D, McCormack E, Mega A, Wanebo HJ. Targeting signaling pathways in cancer therapy. In: Leong SPL, editor. From local invasion to metastatic cancer: involvement of distant sites through the lymphovascular system. New York: Humana Press, 2009. p. 309-26. ISBN 978-1-60327-086-1.

EGFR; RECEPTOR DO FATOR DE CRESCIMENTO EPITELIAL; INIBIDORES DA QUINASE DE TIROSINA; MOLECULAS PEQUENAS; SOLIDAS MALIGNAS DE TUMORES; TERAPIA-ALVO; PREDITORES DE RESPOSTA; CANCER DE MAMA; CARCINOMA HEPATOCELULAR; CANCER DE PULMAO; CANCER DE COLON

91/297US=50 / Câncer
Karrim J, Dubey S. Advances in the treatment of lung cancer. In: Leong SPL, editor. From local invasion to metastatic cancer: involvement of distant sites through the lymphovascular system. New York: Humana Press, 2009. p. 545-52. ISBN 978-1-60327-086-1.

TRATAMENTO DO CANCER DO PULMAO; NEOPLASIAS PULMONARES; QUIMIOTERAPIA; ADJUVANTE; MARCADORES BIOLOGICOS; ANGIOGENESE; RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; INIBIDORES DA PROTEINA QUINASE; ANTICORPOS MONOCLONAIS; RADIOTERAPIA

92/297US=50 / Câncer
Hauschild A, Kahler KC, Egberts F. Sorafenib, a multikinase inhibitor: results from clinical trials in melanoma patients. In: Leong SPL, editor. From local invasion to metastatic cancer: involvement of distant sites through the lymphovascular system. New York: Humana Press, 2009. p. 565-74. ISBN 978-1-60327-086-1.

SORAFENIB. INIBIDOR MULTIQUINASE; PACIENTES COM MELANOMA; MELANOMA; METASTASE; SORAFENIB; INIBIDORES MULTIQUINASE

93/297US=60 / Biol/Mol
Nicholl MB, Hoon DSB. Apoptosis in cutaneous melanoma. In: Chen GG, Lai PBS. Apoptosis in carcinogenesis and chemotherapy: apoptosis in cancer. New York: Springer, 2009. p. 111-25. ISBN 978-1-4020-9596-2.

APOPTOSE; MORTE CELULAR PROGRAMADA; MELANOMA CUTANEO; APAF-1; SURVIVINA; INIBIDORES DE APOPTOSE

94/297US=60 / Biol/Mol
Alin N, MacLeod S, Hine RJ, Chowdhury P. Cellular signaling mechanisms in pancreatic apoptosis. In: Chen GG, Lai PBS. Apoptosis in carcinogenesis and chemotherapy: apoptosis in cancer. New York: Springer, 2009. p. 295-325. ISBN 978-1-4020-9596-2.

APOPTOSE; MORTE CELULAR PROGRAMADA; MECANISMOS DE SINALIZACAO DE APOPTOSE; FOSFATOS DE INOSITOL; NUTRICAO; CARCINOGENESE PANCREATICA; CANCER DE PANCREAS; BIOMARCADORES; INIBIDORES DE CASPASES; FAMILIA IAP; MECANISMOS ACOPLADOS A PROTEINA- G; POLIFOSFATOS DE INOSITOL; BIOMARCADORES; DIETA; ESTRESSE OXIDATIVO

95/297US=64 / Clin/Médica
Senise JF. Infecção por HIV e AIDS: infecção pelo HIV e gestação. In: Focaccia R, editor. Veronesi tratado de infectologia. 4 ed. rev atual. São Paulo: Atheneu, 2009. p. 258-64. ISBN 85-3880101-6.

DOENCA INFECCIOSA; AIDS; HIV; GRAVIDEZ; TRANSMISSAO MATERNO-FETAL DO HIV; TRATAMENTO ANTIRRETROVIRAL; INIBIDORES DA PROTEASE

96/297US=66 / Biol/Mol
Herbert BS, Goldblatt EM. Therapeutic targets and drugs I: telomerase and telomerase inhibitors. In: Hiyama K, editor. Telomeres and telomerase in cancer. New York: Springer, 2009. p. 225-49. (Cancer Drug Discovery and Development) ISBN 978-1-60327-306-0.

ALVOS TERAPEUTICOS E DROGAS I; INIBIDORES DA TELOMERASE; TELOMERASE; HTERT; HTERC; TELOMERASE INIBIDORES DE TELOMERASE DE ATIVIDADE; TELOMEROS; OLIGONUCLEOTIDEOS; TELOMERASE PROTEINAS ASSOCIADAS; CANCER; ENSAIOS CLINICOS

97/297US=66 / Biol/Mol
Punchihewa C, Yang D. Therapeutic targets and drugs II: G-quadruplex and G-quadruplex inhibitors. In: Hiyama K, editor. Telomeres and telomerase in cancer. New York: Springer, 2009. p. 251-80. (Cancer Drug Discovery and Development) ISBN 978-1-60327-306-0.

ALVOS TERAPEUTICOS E MEDICAMENTOS II; G-QUADRUPLEX E G-QUADRUPLEX INIBIDORES; TELOMERO HUMANO; G-QUADRUPLEX; META DROGA ANTICANCER; G-QUADRUPLEX LIGANTES; POLIMORFISMO ESTRUTURA TELOMERICA G-QUADRUPLEX

98/297US=66 / Biol/Mol
Seimiya H, Tsuruo T. Therapeutic targets and drugs III: tankyrase 1, telomere-binding proteins, and inhibitors. In: Hiyama K, editor. Telomeres and telomerase in cancer. New York: Springer, 2009. p. 281-91. (Cancer Drug Discovery and Development) ISBN 978-1-60327-306-0.

ALVOS TERAPEUTICOS E DROGAS III; TELOMERO PROTEINAS DE LIGACAO E INIBIDORES; TANKYRASE 1; TRF1; POLY(ADP-RIBOSIL); SHELTERIN; TRF2; POT1

99/297US=85 / Biol/Mol
Plantivaux A, Szegezdi E, Samali A, Egan L. Is there a role for nuclear factor kB in tumor necrosis factor-related apoptosis-inducing ligand resistance?. In: Diederich M. Natural compounds and their role in apoptotic cell signaling pathways. Boston: Blackwell, 2009. p. 38-49. (Annals of the New York Academy of Sciences Vol 1171) ISBN 978-1-57331-737-5.

CANCER; APOPTOSE; RESISTENCIA; INIBIDORES DE PROTEASSOMA; SUPER-REPRESSOR; MTOR; TRAIL; NF-KB

100/297US=85 / Biol/Mol
Savickiene J, Treigyte G, Magnusson KE, Navakauskiene R. Response of retinoic acid-resistant KG1 cells to combination of retinoic acid with diverse histone deacetylase inhibitors. In: Diederich M. Natural compounds and their role in apoptotic cell signaling pathways. Boston: Blackwell, 2009. p. 321-33. (Annals of the New York Academy of Sciences Vol 1171) ISBN 978-1-57331-737-5.

CADMIO; LEUCEMIA; APOPTOSE; HISTONA DESACETILASE INIBIDORES; REMODELACAO DA CROMATINA; P21

Primeira | Anterior | Próxima | Última